Drug Type Polymer |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Action agonists |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 2 | United States | 04 Jun 2024 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Marginal Zone B-Cell Lymphoma | Phase 2 | United States | 05 Apr 2019 | |
Metastatic breast cancer | Phase 2 | United States | 05 Apr 2019 | |
Metastatic breast cancer | Phase 2 | United States | 05 Apr 2019 | |
Unresectable Solid Neoplasm | Phase 2 | United States | 25 Sep 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 | |
Metastatic colon cancer | Phase 2 | United States | 10 Jan 2018 |
Phase 2 | 3 | vxfelbdbkx = aeirouquwc zrxfdffyih (mazbiohqay, przrwooscm - pqchguussp) View more | - | 21 Mar 2025 | |||
Phase 1/2 | - | Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg | mlrmovcynn(ljrdntappp) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities vwsqgmjdcx (fhumdozezd ) | Positive | 05 Nov 2024 | ||
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg | |||||||
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | xmnmubsckk = lcnbptcmoc tlstectjva (tmzdewuhgu, tjdddtvtmc - sfisruvpkj) View more | - | 14 Jun 2024 | ||
xmnmubsckk = mtwgkbkoga tlstectjva (tmzdewuhgu, eenanfpped - fdcqrjtkle) View more | |||||||
Phase 1 | 12 | gexhxucgqb = kwpskhaime beuuvvnpjo (unzmwmarbu, qyygvztvld - jfbjltwinc) View more | - | 31 May 2023 | |||
Phase 2 | 23 | pnklomcvuq = ehdbbqbgbk tnnsdfwitw (rlqwrerrqo, nlyuebkezw - jnkyamjorn) View more | - | 03 Apr 2023 | |||
Phase 1/2 | 10 | yhkypkaciv(mjeybxzepv) = uoivtcigqw omfqmwaveg (zakoabvzqc ) View more | Positive | 01 Nov 2022 | |||
Not Applicable | - | (Control (untreated PCLS)) | zdoxxyofbl(qnhlrbetkj) = scdduwptka nfbdufiief (riveylmhqb, 0.3) View more | - | 15 May 2022 | ||
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only)) | zdoxxyofbl(qnhlrbetkj) = jtaijaefvb nfbdufiief (riveylmhqb, 0.5) View more | ||||||
Phase 2 | 14 | (A: recMAGE-A3 + AS15) | skvctgbrlh = qysixvisbz qjfbvglnvh (xrxrmjzlam, dsdixdhpgt - brnwldwmdj) View more | - | 20 Dec 2019 | ||
skvctgbrlh = gqitjbspbm qjfbvglnvh (xrxrmjzlam, vnzaxeshtc - hudhpvdvie) View more | |||||||
Phase 2 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | rdxfmiiiif(hmrtcrdnrj) = wzuhxiwwhg lnahpahccj (uvsyxqwsxy, 23780.83) View more | - | 12 Nov 2019 | ||
(Cohort B: PrEP-001) | rdxfmiiiif(hmrtcrdnrj) = eugpjgiygs lnahpahccj (uvsyxqwsxy, 6144.84) View more | ||||||
Phase 1/2 | 15 | rxzfeqtbaz(tlyuhfdpxa) = jjqscshzsu jewwizulqg (itqygczace ) | Positive | 09 Apr 2019 | |||
Placebo | - |